BRANFORD, Conn. --(BUSINESS WIRE)--Sep. 6, 2024-- Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it announced today that Travis Whitfill , COO, will present an overview of the Company at the H.C. Wainwright 23rd Annual Global Investment Conference , being held
BRANFORD, Conn. --(BUSINESS WIRE)--Aug. 28, 2024-- Azitra, Inc. (NYSE American: AZTR), a precision dermatology company, announced that it has initiated dosing the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of Netherton syndrome.
New investigational new drug (IND) application cleared to proceed by the US FDA for a Phase 1/2 clinical study of ATR-04 for moderate to severe EGFR inhibitor (“EGFRi”) associated dermal toxicity. There are an estimated 150,000 patients with EGFRi-associated skin rash in the US, representing a > $1
BRANFORD, Conn. --(BUSINESS WIRE)--Aug. 20, 2024-- Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it has successfully screened the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of Netherton syndrome.
BRANFORD, Conn. --(BUSINESS WIRE)--Aug. 12, 2024-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024 , and provided a business
BRANFORD, Conn. --(BUSINESS WIRE)--Jul. 25, 2024-- Please replace the release with the following corrected version due to multiple revisions. The updated release reads: AZITRA, INC. ANNOUNCES CLOSING OF $10.0 MILLION PUBLIC OFFERING Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage
BRANFORD, Conn. --(BUSINESS WIRE)--Jul. 23, 2024-- Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of a public offering of an aggregate of 6,665,000 shares of
Newly issued U.S. patent protects a filaggrin-secreting strain of Staphylococcus epidermidis for the treatment of atopic dermatitis. Issuance date was July 16, 2024 Newly allowed patents in the U.S. and China protect the composition of a filaggrin-secreting strain of Staphylococcus epidermidis
Common Stock Will Begin Trading on a Split-Adjusted Basis on July 1, 2024 BRANFORD, Conn. --(BUSINESS WIRE)--Jun. 27, 2024-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it
BRANFORD, Conn. --(BUSINESS WIRE)--May 31, 2024-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the 2024 BIO International Convention being held